Delivery Order SPE2DB24D3013-SPE2DB26FFFZX
- Not listed
- The Defense Logistics Agency awarded a $1,632.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 ml pen (0.5 ml), a diabetes medication. The order was competitively awarded with no set-aside designation and is scheduled for completion by October 27, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance, aligning with the company's role as a primary pharmaceutical distributor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,632.54 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen (0.5 ml), a diabetes medication. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The contract was awarded on October 21, 2025, with an ultimate completion date of October 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,635.27 for Mounjaro 5 mg/0.5 mL pen (0.5 mL), a diabetes medication, with an ultimate completion date of July 15, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,899.65 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on August 25, 2025, with completion targeted for August 26, 2025. This firm fixed-price, competitively awarded delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract procures a diabetes medication used across military and federal healthcare systems...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,176.72 for Mounjaro 10 mg/0.5 ml pen (0.5ml) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed price, non-set-aside contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction for this diabetes medication under a larger contract vehicle. This award is a child delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,632.54 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 ml pens (0.5 ml units), a diabetes management medication. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by September 19, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL), a diabetes medication. This competitively awarded, firm fixed price delivery order is scheduled for completion by August 25, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,265.08 to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pen injectors on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a single delivery transaction for this diabetes medication as part of the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,812.48 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on October 21, 2025, with an ultimate completion date of October 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,018.76 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on October 17, 2025, with completion targeted for October 20, 2025. This competitively awarded, non-set-aside order utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB26FFFZXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,204.11 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 ml pen (0.5ml), a diabetes management medication. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of November 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified pharmaceutical distributors. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion comprehensive global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen Drug Corp has demonstrated substantial capability in fulfilling military and veteran healthcare pharmaceutical needs through this prime contract vehicle, which enables the company to supply a broad range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 10/31/25 |